Sarepta Therapeutics (NasdaqGS:SRPT) reported positive three year functional results from its Phase 3 EMBARK trial of ...

ETHealthworld.com brings latest duchenne muscular dystrophy news, views and updates from all top sources for the Indian Health industry.

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.

Sarepta Therapeutics (NASDAQ:SRPT) reported three-year top-line results from its EMBARK Phase 3 pivotal trial evaluating ...

Sarepta Therapeutics SRPT announced positive three-year top-line data from Part 1 of the phase III EMBARK study, evaluating ...

Panelists discuss how the pooled 3-year data for delandistrogene moxeparvovec show sustained motor function stabilization and less deterioration compared with natural history, providing confidence in ...

Capricor Therapeutics has presented positive long-term data from its HOPE-2 clinical trial at the 2025 Muscular Dystrophy Association Conference, indicating that its leading treatment, deramiocel, can ...

Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing innovative therapies for patients with ...

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular dystrophies like FSHD and myotonic dystrophy, using strategies to knock down ...

AMSTERDAM, Oct 13 (Reuters) - Dutch biotech company Amsterdam Molecular Therapeutics said its gene therapy treatment for Duchenne muscular dystrophy had been granted orphan drug designation by the ...

The US Food and Drug Administration (FDA) has approved the antisense oligonucleotide casimersen (Amondys 45, Sarepta Therapeutics) injection for the treatment of patients with Duchenne muscular ...